Roche’s diagnostics business continues to be buffeted by China headwinds, but the Swiss major believes it has enough ...

Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions that the Japanese business took earlier ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Parikh is backed up by experienced CRO leader William Gannon Jr., M.D., who is LyfeSci’s chief medical officer. Gannon has ...

Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) ...

Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...

Thermo Fisher Scientific’s plan for growth is paying off as the biopharma service provider and supplier posted a sales bump ...

Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the ...